Dr. Gibson’s research focuses on clinical pathogenesis interstitial lung diseases including idiopathic pulmonary fibrosis, Sarcoidosis, autoimmune lung disease, and Occupational lung disease. Dr. Gibson conducts studies that include early and late phase clinical trials of novel therapeutics in interstitial lung disease, the discovery of biomarkers of disease activity and progression, and clinical translational studies of disease pathogenesis. He has published a number of translational studies to identify unique biomarkers of disease activity in idiopathic pulmonary fibrosis and other interstitial lung diseases, studies of novel interventions in acute IPF exacerbations, as well as studies of gene expression profiling in IPF lungs. He has discovered a number of peripheral blood biomarkers that have been useful predicting disease progression in idiopathic pulmonary fibrosis. He has participated in multinational Studies of the genetics of IPF and Sarcoidosis.
Dr. Gibson is the medical director of the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease. He is in charge of all clinical research in the center and has an active consultative practice focusing on all of the diffuse parenchymal lung diseases including the idiopathic interstitial pneumonias, autoimmune lung diseases, hypersensitivity pneumonitis, genetic-based interstitial lung diseases, and Sarcoidosis. He is principal investigator on a large number of government-sponsored and industry-funded clinical trials of novel therapeutic agents and therapeutic approaches to disease such as idiopathic pulmonary fibrosis, Sarcoidosis, and pulmonary fibrosis from secondary causes.
Dr. Gibson's educational activities in the school of medicine have focused on the idiopathic interstitial pneumonias, occupational lung diseases, and Sarcoidosis.
- BA, Drew University, 1976
- MD, UMDNJ - Rutgers Medical School, 1980
- Residency, Internal Medicine, Emory University, 1983
- Fellowship, Pulmonary and Critical Care, University of Pittsburgh School of Medicine, 1987
Education & Training
Huang, Y, Ma, SF, Vij, R, Oldham, J, Herazo-Maya, J, Broderick, S, Strek, ME, White, SR, Hogarth, DK, Sandbo, NK, Lussier, YA, Kaminski, N, Garcia, JGN, North, I, Gibson, KF. A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulmonary Medicine. 2015; Nov 21;15: 147.
Raghu, G, Martinez, FJ, Brown, KK, Costabel, U, Cottin, V, Wells, AU, Lancaster, L, Gibson, KF, Haddad, T, Agarwal, P, Mack, M, Dasgupta, B, Nnane, IP, Flavin, SK, Barnathan, ES. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J. 2015; Oct 22
Moller, DR, Koth, LL, Maier, LA, Morris, A, Drake, W, Rossman, M, Leader, JK, Collman, RG, Hamzeh, N, Sweiss, NJ, Zhang, Y, O'Neal, S, Senior, RM, Becich, M, Hochheiser, HS, Kaminski, N, Wisniewski, SR, Gibson, KF. GRADS Sarcoidosis Study Group. Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study (GRADS): Sarcoidosis Protocol. Ann Am Thorac Soc. 2015; Oct;12(10): 1561-71.
Donahoe, M, Valentine, VG, Chien, N, Gibson, KF, Raval, JS, Saul, M, Xue, J, Zhang, Y, Duncan, SR. Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis. PLoS One. 2015; Jun 17;10(6): e0127771.
Han, S, Lear, TB, Jerome, JA, Rajbhandari, S, Snavely, CA, Gulick, DL, Gibson, KF, Zou, C, Chen, BB, Mallampalli, RK. Lipopolysaccharide primes the NALP3 inflammasome by inhibiting its ubiquitination and degradation mediated by the SCFFBXL2 E3 ligase. J Biol Chem. 2015; Jun 2 (Epub ahead of print)
Bauer, Y, Tedrow, J, de Bernard, S, Birker-Robaczewska, M, Gibson, KF, Juan Guardela, B, Hess, P, Klenk, A, Lindell, KO, Poirey, S, Renault, B, Rey, M, Weber, E, Nayler, O, Kaminski, N. A Novel Genomic Signature with Translational Significance for Human Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2015; Feb;52(2): 217-31.
Schneider, F, Aggarwal, R, Bi, D, Gibson, K, Oddis, C, Yousem, SA. The Pulmonary Histopathology of Anti-KS Transfer RNA Synthetase Syndrome. Arch Pathol Lab Med. 2015; Jan;139(1): 122-5.
Wilkes, DS, Chew, T, Flaherty, KR, Frye, S, Gibson, KF, Kaminski, N, Klemsz, MJ, Lange, W, Noth, I, Rothhaar, K. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. Eur Respir J. 2015; Jan 22
Peljto, AL, Zhang, Y, Fingerlin, TE, Ma, SF, Garcia, J, Richards, TJ, Silveiri, LJ, Lindell, KO, Steele, MP, Loyd, JE, Gibson, KF, Seibold, MA, Brown, KK, Talbert, JL, Markin, C, Kossen, K, Seiwert, SD, Murphy, E, Noth, I, ...et all. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013; June 5;309(21): 2232-9.
Fingerlin, TE, Murphy, E, Zhang, W, Peljto, AL, Brown, KK, Steele, MP, Loyd, JE, Cosgrove, GP, Lynch, D, Groshong, S, Collard, HR, Wolters, PJ, Bradford, WZ, Kossen, K, Seiwert, SD, du Bois, RM, Garcia, CK, Devine, MS, Gibson, KF, ....et all. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013; Jun;45(6): 613-20.
- Best Doctors in America, 2007-2016
- Pittsburgh Courier's "50 Men of Excellence", 2011
- University of Pittsburgh Innovator Award, 2012
